BNP Paribas Financial Markets’s Nektar Therapeutics NKTR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.34M Sell
19,200
-102,339
-84% -$7.49M ﹤0.01% 3114
2026
Q1
$8.74M Sell
121,539
-88,759
-42% -$5.05M ﹤0.01% 1644
2025
Q4
$8.89M Buy
210,298
+209,864
+48,356% +$11.7M ﹤0.01% 1689
2025
Q3
$24.7K Buy
434
+210
+94% +$6.95K ﹤0.01% 4858
2025
Q2
$5.79K Sell
224
-19,248
-99% -$216K ﹤0.01% 4942
2025
Q1
$199K Sell
19,472
-1,374
-7% -$18K ﹤0.01% 3703
2024
Q4
$291K Buy
20,846
+4,923
+31% +$86.8K ﹤0.01% 3658
2024
Q3
$311K Buy
15,923
+15,118
+1,878% +$288K ﹤0.01% 3059
2024
Q2
$15K Buy
805
+627
+352% +$13.2K ﹤0.01% 3679
2024
Q1
$2.49K Sell
178
-16,046
-99% -$168K ﹤0.01% 3795
2023
Q4
$137K Sell
16,224
-173
-1% -$1.31K ﹤0.01% 3325
2023
Q3
$146K Buy
16,397
+5,560
+51% +$53.5K ﹤0.01% 3216
2023
Q2
$93.5K Buy
10,837
+1,144
+12% +$12.2K ﹤0.01% 3276
2023
Q1
$102K Buy
9,693
+5,786
+148% +$175K ﹤0.01% 3325
2022
Q4
$132K Sell
3,907
-2,822
-42% -$137K ﹤0.01% 3144
2022
Q3
$323K Sell
6,729
-14,231
-68% -$847K ﹤0.01% 3255
2022
Q2
$1.19M Buy
20,960
+4,904
+31% +$309K ﹤0.01% 2092
2022
Q1
$1.3M Buy
16,056
+7,539
+89% +$1.12M ﹤0.01% 2135
2021
Q4
$1.73M Buy
8,517
+3,617
+74% +$785K ﹤0.01% 2168
2021
Q3
$1.32M Buy
4,900
+319
+7% +$76.7K ﹤0.01% 2187
2021
Q2
$1.18M Sell
4,581
-145
-3% -$40.1K ﹤0.01% 2081
2021
Q1
$1.42M Buy
4,726
+226
+5% +$70.3K ﹤0.01% 1910
2020
Q4
$1.15M Buy
4,500
+1,043
+30% +$270K ﹤0.01% 1935
2020
Q3
$860K Sell
3,457
-133
-4% -$41.8K ﹤0.01% 1892
2020
Q2
$1.25M Sell
3,590
-13,095
-78% -$4.09M ﹤0.01% 1696
2020
Q1
$4.47M Sell
16,685
-4,540
-21% -$1.4M 0.01% 1033
2019
Q4
$6.87M Buy
21,225
+14,245
+204% +$4.13M 0.01% 1031
2019
Q3
$1.91M Buy
6,980
+1,949
+39% +$715K ﹤0.01% 1536
2019
Q2
$2.69M Sell
5,031
-235
-4% -$118K 0.01% 1321
2019
Q1
$2.65M Buy
5,266
+1,368
+35% +$811K 0.01% 1279
2018
Q4
$1.92M Sell
3,898
-3,736
-49% -$2.26M ﹤0.01% 1325
2018
Q3
$6.98M Sell
7,634
-5,220
-41% -$4.46M 0.01% 989
2018
Q2
$9.41M Buy
12,854
+9,016
+235% +$10.4M 0.02% 823
2018
Q1
$6.12M Sell
3,838
-2,316
-38% -$2.98M 0.01% 905
2017
Q4
$5.51M Sell
6,154
-1,352
-18% -$800K 0.01% 997
2017
Q3
$2.7M Buy
7,506
+2,066
+38% +$646K 0.01% 1005
2017
Q2
$1.6M Buy
5,440
+294
+6% +$85K ﹤0.01% 1306
2017
Q1
$1.81M Buy
5,146
+569
+12% +$128K ﹤0.01% 1101
2016
Q4
$842K Buy
4,577
+641
+16% +$130K ﹤0.01% 1425
2016
Q3
$1.01M Sell
3,936
-1,461
-27% -$376K ﹤0.01% 921
2016
Q2
$1.15M Buy
5,397
+1,306
+32% +$292K 0.01% 1115
2016
Q1
$844K Sell
4,091
-5,522
-57% -$1.06M ﹤0.01% 1070
2015
Q4
$2.43M Buy
9,613
+3,331
+53% +$685K 0.01% 862
2015
Q3
$1.03M Buy
6,282
+1,227
+24% +$217K ﹤0.01% 1039
2015
Q2
$949K Buy
5,055
+4,690
+1,285% +$807K ﹤0.01% 1139
2015
Q1
$60.1K Buy
365
+219
+150% +$45K ﹤0.01% 1869
2014
Q4
$33.9K Sell
146
-380
-72% -$81.2K ﹤0.01% 1731
2014
Q3
$95.2K Buy
526
+517
+5,744% +$98.9K ﹤0.01% 2214
2014
Q2
$1.81K Sell
9
-2
-18% -$354 ﹤0.01% 3163
2014
Q1
$1.86K Sell
11
-89
-89% -$17.6K ﹤0.01% 2683
2013
Q4
$17K Sell
100
-2,021
-95% -$326K ﹤0.01% 2317
2013
Q3
$332K Sell
2,121
-566
-21% -$105K ﹤0.01% 1843
2013
Q2
$466K Buy
+2,687
New +$412K ﹤0.01% 1614

Other funds holding NKTR

BNP Paribas Financial Markets's NKTR Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Nektar Therapeutics (NKTR) stake by 84% in Q2 2026, selling an estimated $7.49M and leaving 19,200 shares worth $1.34M. The position accounts for ﹤0.01% of the portfolio, ranked #3114.

BNP Paribas Financial Markets first reported a position in NKTR in Q2 2013 and has held it in 53 quarters since. The position peaked at $9.41M in Q2 2018. 219 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • BNP Paribas Financial Markets held 19,200 shares of Nektar Therapeutics worth $1.34M as of Q2 2026.
  • BNP Paribas Financial Markets sold 102,339 Nektar Therapeutics shares in Q2 2026, an estimated $7.49M.
  • Nektar Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3114 holding.
  • BNP Paribas Financial Markets first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • BNP Paribas Financial Markets's Nektar Therapeutics position peaked at $9.41M in Q2 2018.
  • 219 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.